Key facts, as of
As of November 2, 2026, Insulet Corporation (PODD) trades at $152.95, down 51.1% over the past year. Its 52-week range runs from $126.40 to $354.88; the price is 56.9% below that high. It is 56.9% below its all-time high of $354.88, reached in November 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +303.2%, against +316.3% for the S&P 500 (SPY). It sits 14.1% below its 200-day average of $178.13. Its 30-day volatility is 29.2% annualized, which we rate medium risk. It has a trailing P/E of 28.6. Insulet Corporation (PODD) has confirmed its next earnings report for November 4, 2026, before the market opens (date from Yahoo Finance, listed on our November 2026 earnings calendar).
Cite: Portfolio Terminal, "Insulet Corporation (PODD) stock analysis", 2026-11-02. https://portfolio-terminal.com/analyse/podd
Where it trades today
trading 12% of the way up its 52-week range
How the price has moved
How far it is from its record
Insulet Corporation (PODD) is 56.9% below its all-time high of $354.88, reached in November 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +303.2%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- PODD closes above its 50-day average ($141.01) while the 50-day is still under the 200-day ($178.13): a rebound inside a longer decline, not yet an uptrend.
- At $152.95, PODD is 56.9% below its 1-year high of $354.88, set on November 20, 2025, and 21.0% above its 1-year low of $126.40 (August 5, 2026).
- Over the past month PODD rose 16.1%, from $131.69 to $152.95.
- PODD trades at 28.6x its last twelve months of earnings and 19.8x the next twelve months' estimate, so analysts expect earnings 44.6% higher.
- Its P/E is 12.0% below the 32.6x median of the 3 other medical devices companies we track (ABT, SYK, BSX).
- PODD's 30-day volatility, 29.2% a year, works out to a typical daily move of about 1.8%.
- Yahoo Finance puts its beta at 1.05: over five years of monthly returns, PODD moved about 1.05% for each 1% move of the S&P 500.
What would change the read
- The rebound holds while it closes above the 50-day average, $141.01 (−7.8%); it becomes an uptrend when the 50-day climbs 26.3% to cross the 200-day at $178.13.
- A close above $354.88 (+132.0%) would be a new 1-year high; below $126.40 (−17.4%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for PODD, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under medical devices among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for PODD by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for PODD. Last refresh: Nov 2, 2026, 7:10 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Medical Devices.
What Insulet Corporation does
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also…
What analysts expect
PODD carries a buy consensus from 23 analysts, with an average price target of $167.17 versus $152.95 today (+9.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
PODD generated $3.05B in trailing revenue (23.5% year over year), with a 12.3% net margin, and $236.90M of free cash flow, against $480.60M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $2.71B | $1.94B | $473.80M | $247.10M | $3.51 | $349.90M |
| 2024 | $2.07B | $1.45B | $308.90M | $418.30M | $5.97 | $296.20M |
| 2023 | $1.70B | $1.16B | $220.10M | $206.30M | $2.96 | $36.50M |
| 2022 | $1.31B | $805.60M | $37.60M | $4.60M | $0.07 | -$38.30M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
PODD is in 14 of the 54 ETFs we track. It weighs most in RSP: 0.20% of the fund, holding #199 of 504.
Famous investors who hold it
PODD is in the latest 13F of 1 of the 15 famous investors we follow. Ray Dalio (Bridgewater Associates) holds the most of it: 0.10% of the portfolio, position #171 of 992, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
PODD beside the other companies Yahoo Finance files under medical devices among the assets we track (ABT, SYK, BSX, largest first).
PODDyou are here$152.95$10.61B
ABTAbbott Laboratories$110.11$190.53B
SYKStryker Corporation$305.71$116.38B
BSXBoston Scientific$44.12$63.94BWhat the chart is saying
Back above its 50-day average, still under the long-term trend.
recovering- Price is 8.5% above its 50-day average and 14.1% below its 200-day.
- RSI at 67 is neither stretched nor washed out.
- The nearest ceiling is $168.84 (+10.4%), the nearest floor $144.52 (-5.5%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is PODD valued right now?
Insulet Corporation trades at 28.6 times its last twelve months of earnings and 19.8 times the next twelve months' estimate (Yahoo Finance, November 2, 2026). On the chart: back above its 50-day average, still under the long-term trend. Price is 8.5% above its 50-day average and 14.1% below its 200-day.
What is the risk level of PODD?
Based on 30-day volatility of 29.2%, PODD has MEDIUM risk. Its beta of 1.05 means it has swung more than the S&P 500 over the last five years.
Does PODD pay dividends?
Yahoo Finance shows no dividend yield for Insulet Corporation (November 2, 2026).
How far is PODD from its all-time high?
Insulet Corporation is 56.9% below its all-time high of $354.88, reached in November 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +303.2%, against +316.3% for the S&P 500 (SPY).
When does Insulet Corporation report earnings?
Insulet Corporation (PODD) reports its next quarterly earnings on Wednesday, November 4, 2026, before the market opens. The company has confirmed the date; it comes from Yahoo Finance's earnings data and is listed on the Portfolio Terminal November 2026 earnings calendar. For that quarter, the analysts' consensus Yahoo Finance reports is earnings of $1.59 per share.
Which ETFs hold PODD?
14 of the 54 popular ETFs we track hold Insulet Corporation. The largest weights: RSP (0.20%), XLV (0.15%), VB (0.11%), IWF (0.03%) and SPYG (0.03%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is PODD?
0.01%, as of September 30, 2026: PODD is holding #484 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.14 in Insulet Corporation.
Which famous investors own PODD?
Ray Dalio (0.10% of Bridgewater Associates's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for PODD?
The average analyst price target for Insulet Corporation (PODD) is $167.17 based on 23 analyst estimates, about 9.3% above the current price of $152.95. The published range runs from $143.00 to $215.00.
How much revenue does PODD generate?
Insulet Corporation reported $3.05B in trailing twelve-month revenue. Revenue growth is running at 23.5% year over year. Net margin sits at 12.3%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare PODD with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.